-
公开(公告)号:WO2019130052A1
公开(公告)日:2019-07-04
申请号:PCT/IB2018/001462
申请日:2018-12-24
CPC分类号: A61K9/16 , A61K9/0095 , A61K9/08 , A61K9/107 , A61K31/44 , A61K31/4985 , A61K31/506 , A61K31/519 , A61K31/53 , A61K47/10
摘要: The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.
-
公开(公告)号:WO2019123332A1
公开(公告)日:2019-06-27
申请号:PCT/IB2018/060368
申请日:2018-12-19
发明人: ARDEMAGNI, Franco
CPC分类号: A61K9/0014 , A61K9/0031 , A61K9/0034 , A61K9/0043 , A61K9/006 , A61K9/0063 , A61K9/007 , A61K9/06 , A61K31/197 , A61K41/0061 , A61K47/10
摘要: A pharmaceutical preparation is disclosed herein, comprising a topically released active ingredient such as 5-aminolevulinic acid, and a heat-sensitive carrier comprising, by weight based on the total weight of the preparation, 19 to 24 wt% Poloxamer P407 and 4 % to 8 % wt% Poloxamer P188, the balance being composed of water and any pharmaceutically acceptable excipients and/or additives. The above composition has improved mucoadhesion and active ingredient release as well as suitable rheological and so-gel transition temperature characteristics, which make it particularly suitable for treatment of pathological conditions or lesions of the skin or the mucosa preferably by photodynamic therapy.
-
公开(公告)号:WO2019118574A1
公开(公告)日:2019-06-20
申请号:PCT/US2018/065171
申请日:2018-12-12
发明人: MCGLONE, John J.
IPC分类号: C12Q1/68
CPC分类号: A61K31/5685 , A61K9/0043 , A61K9/007 , A61K9/008 , A61K9/122 , A61K9/124 , A61K31/47 , A61K31/568 , A61K47/06 , A61K47/08 , A61K47/10 , A61K47/20 , A61K47/24 , A61K47/44 , A61P15/08
摘要: The present disclosure provides for pheromonal compositions and methods of using the compositions for stimulating early onset of estrus in a peri-pubertal suid and methods of improving performance of the peri-pubertal female suid. The composition may comprise at least one steroid hormone and a heterocyclic aromatic compound. The method comprises administering the pheromone composition to the suid for a period of time.
-
公开(公告)号:WO2019111917A1
公开(公告)日:2019-06-13
申请号:PCT/JP2018/044633
申请日:2018-12-05
申请人: ライオン株式会社
IPC分类号: A61K31/01 , A61K9/107 , A61K47/08 , A61K47/10 , A61K47/14 , A61K47/18 , A61K47/22 , A61K47/24 , A61K47/44 , A61P27/02 , A61P27/04
CPC分类号: A61K9/107 , A61K31/01 , A61K47/08 , A61K47/10 , A61K47/14 , A61K47/18 , A61K47/22 , A61K47/24 , A61K47/44 , A61P27/02 , A61P27/04
摘要: (A)流動パラフィンと、(B)非イオン界面活性剤と、(C)テルペノイドとを含有し、(B)/(A)で表される(A)成分と(B)成分との配合質量比が3≦(B)/(A)≦25であり、(C)成分の配合量が0.0001~0.5w/v%である水性眼科用組成物。
-
公开(公告)号:WO2019109065A1
公开(公告)日:2019-06-06
申请号:PCT/US2018/063573
申请日:2018-12-03
发明人: KOHANE, Daniel S. , ZHAO, Chao
CPC分类号: A61K47/60 , A61K9/0019 , A61K47/10
摘要: Anesthetics covalently conjugated onto biodegradable and biocompatible hydrophilic polymers via hydrolysable linkages provide controlled release of local anesthetics in vivo in an effective amount for nerve blockade with reduced toxicity relative to the unconjugated anesthetic agent. The rate of anesthetic release can be tuned by changing the hydrophilicity of the polymer. Exemplary formulations of Poly (glycerol sebacate) (PGS), optionally including Poly ethylene glycol (PEG) polymers conjugated to Tetrodotoxin (TTX) (PGS-PEG-TTX and PGS-TTX), and methods of use thereof are provided Nerve blockade from PGS-PEG-TTX and PGS-TTX was associated with minimal systemic and local toxicity to the muscle and the peripheral nerves. TDP-TTX conjugates homogeneously dispersed into PEG200 are also described. PEG200 not only worked as a medium, but also worked as a chemical permeation enhancer (CPE) to enhance the effectiveness of TTX.
-
公开(公告)号:WO2019108747A1
公开(公告)日:2019-06-06
申请号:PCT/US2018/062982
申请日:2018-11-29
申请人: ZOETIS SERVICES LLC
IPC分类号: A61L27/44 , A61L27/46 , A61L27/50 , A61L31/12 , A61L31/14 , A61K9/00 , A61K47/10 , A61K47/12 , A61K47/36
CPC分类号: A61K31/722 , A61K9/0024 , A61K9/0041 , A61K9/06 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/36 , A61L27/446 , A61L27/46 , A61L27/50 , A61L31/127 , A61L31/128 , A61L31/14 , A61L2400/06 , A61P15/14 , C08L5/08
摘要: The present application provides compositions configured to be provided in a flowable, liquid form but that are configured to transition to a solid or semi-solid gel based upon a change in pH. The change in pH can arise from one or more materials utilized in the composition itself or based upon encountering an environment with a significantly different pH. The compositions are particularly suited for use as a teat sealant in non-human mammals, particularly cattle.
-
公开(公告)号:WO2019100007A1
公开(公告)日:2019-05-23
申请号:PCT/US2018/061833
申请日:2018-11-19
申请人: TILRAY, INC.
IPC分类号: A61K31/01 , A61K31/015 , A61K31/045
CPC分类号: A61K31/352 , A61K9/00 , A61K9/006 , A61K31/05 , A61K47/06 , A61K47/10 , A61K47/14 , A61K47/24 , A61K47/44
摘要: Compositions for administering cannabinoid, including edible forms of cannabinoids. Phospholipids and waxes may be used to control the onset timing of cannabis drug effects.
-
公开(公告)号:WO2019087888A1
公开(公告)日:2019-05-09
申请号:PCT/JP2018/039452
申请日:2018-10-24
申请人: 富士フイルム株式会社
IPC分类号: A01N31/16 , A01N25/02 , A01N25/06 , A01N25/34 , A01N33/04 , A01N37/10 , A01N37/40 , A01N43/08 , A01N43/16 , A01N43/40 , A01N43/60 , A01N65/08 , A01P1/00 , A01P3/00 , A61K9/06 , A61K9/08 , A61K9/12 , A61K31/05 , A61K31/137 , A61K31/14 , A61K31/166 , A61K31/192 , A61K31/216 , A61K31/235 , A61K31/353 , A61K31/375 , A61K31/4412 , A61K31/498 , A61K31/618 , A61K31/7024 , A61K36/44 , A61K47/10 , A61P31/04 , A61P31/14
CPC分类号: A01N25/02 , A01N25/06 , A01N25/34 , A01N31/16 , A01N33/04 , A01N37/10 , A01N37/40 , A01N43/08 , A01N43/16 , A01N43/40 , A01N43/60 , A01N65/08 , A61K9/06 , A61K9/08 , A61K9/12 , A61K31/05 , A61K31/137 , A61K31/14 , A61K31/166 , A61K31/192 , A61K31/216 , A61K31/235 , A61K31/353 , A61K31/375 , A61K31/4412 , A61K31/498 , A61K31/618 , A61K31/7024 , A61K36/44 , A61K47/10 , A61P31/04 , A61P31/14
摘要: 本発明の課題は、抗ウイルス活性が優れる組成物を提供することである。また、本発明の他の課題は、上記組成物を用いた、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、及び、ワイパーを提供することである。 本発明の組成物は、式(1)で表される化合物中の、水酸基中の水素原子以外の水素原子を1個以上除いた残基を2個以上有する化合物A、式(2)で表される化合物B、式(3)で表される化合物C、及び、式(4)で表される化合物D、からなる群から選択される1種以上の化合物、ならびに、アルコールを少なくとも含む溶媒、を含む組成物であって、 上記アルコールの含有量が、上記溶媒全体積に対して、40~100体積%であり、 pHが9.5超14.0以下である。
-
公开(公告)号:WO2019049081A1
公开(公告)日:2019-03-14
申请号:PCT/IB2018/056847
申请日:2018-09-07
IPC分类号: A61K9/00 , A61K47/10 , A61K47/18 , A61K47/20 , A61K9/08 , A61K9/10 , A61K31/57 , A61P15/00 , A61P35/00
CPC分类号: A61K9/0019 , A61K9/08 , A61K9/10 , A61K31/57 , A61K47/10 , A61K47/183 , A61K47/20 , A61P15/00 , A61P35/00
摘要: The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml or about 160 mg/ml to 240 mg/ml medroxyprogesterone acetate, 1.2 mg/ml to 3.0 mg/ml docusate sodium, polyethylene glycol, and water. Methods of using these compositions are also described.
-
公开(公告)号:WO2019048906A1
公开(公告)日:2019-03-14
申请号:PCT/IB2017/055404
申请日:2017-09-07
CPC分类号: A61K9/0019 , A61K9/10 , A61K31/57 , A61K47/10 , A61K47/183 , A61K47/20
摘要: The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml or about 160 mg/ml to 240 mg/ml medroxyprogesterone acetate, 1.7 mg/ml to 2.3 mg/ml docusate sodium, polyethylene glycol, and water. Methods of using these compositions are also described.
-
-
-
-
-
-
-
-
-